Interference with the urokinase plasminogen activator system: A promising therapy concept for solid tumours

Expert Opinion on Biological Therapy

Volumn 1, Issue 4, 2001, Pages 683-691

  Muehlenweg, Bernd ^a   Sperl, Stefan ^b   Magdolen, Viktor ^c   Schmitt, Manfred ^a   Harbeck, Nadia ^a,d  

^a Wilfx AG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Technische Universität München ^*  (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene therapy; Invasion; Metastasis; PAI 1; Plasminogen activator system; Synthetic inhibitors; Tumour therapy; Upa; Upa r (cd87)

Indexed keywords

CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; SERINE PROTEINASE INHIBITOR; UROKINASE;

ANIMAL; CHEMICAL STRUCTURE; CLINICAL TRIAL; GENE THERAPY; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANIMAL; CLINICAL TRIALS; GENE THERAPY; HUMAN; MOLECULAR STRUCTURE; NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; SERINE PROTEINASE INHIBITORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035408087     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.4.683     Document Type: Article

References (71)

1. ANDREASEN PA, KJÖLLER L, CHRISTENSEN L, DUFFYMJ: The urokinase-type plasminogen aaivator system in cancer metastasis: a review. Int. J. Cancer (1997) 72:1-22.
2. SCHM1TT M, HARBECK N, THOMSSEN C etal: Clinical impact of the plasminogen activator system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemostasis (1997) 78(l):285-296.
3. SCHMITT M, WILHELM O, REUNING U ctaL: The uroldnase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis (2000) 14(2/3):! 14132.
4. •• Review on the uPA system in cancer invasion and metastasis.
5. SCHMITT M.JANICKEKGRAEFFH: Tumor-associated proteases. Fibrinolysis (1992) 6:3-26.
6. REUNING U, MAGDOLEN V, WILHELM O etal: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncology (1998) 13:893-906.
7. • Review of the prognostic relevance for the urokinasc system in different cancer types.
8. HARBECK N, THOMSSEN C, BERGER U et al.: Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res. Treat. (1999) 54:147-157.
9. JÄNICKE F, PRECHTL A, THOMSSEN C etaL: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator inhibitor type I.J. NatL Cancer Inst. (2001) 93:913-920.
10. •• Interim analyses on the significance of uPA and PAI-1 in cancer.
11. SCHMALFELDTB.KUHNW, REUNING U etaL: Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. (1995) 55:3958-3963.
12. NOACKF, SCHMITT M, BAUER J et al.: A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications. Int. J.
13. Biol. Markers (2000) 15(1):100-104.
14. HEISS MM, ALLGAYERH, GRUETZNER KU et al: Individual development and uPA-Receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med. (1995) 1:1035-1039.
15. DUFFY MJ: Proteases as prognostic markers in cancer. Clin. Cancer Res. (1996) 2: 613-618.
16. KOS J, LAH TT: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncology Reports (1998) 5:1349-1361.
17. HARBECKN. ALT U, BERGER U et al: Long-term follow-up confirms prognostic impact of PAI-1 and cathepsins D and L in primary breast cancer. Int. J. BioL Markers (2000) 15:79-83.
18. KUTE TE, GRØHNDAHL-HANSEN J, SHAO SM, LONG R, RUSSELL G, BRÜNNER N: Low cathepsin D and low plasminogen activator Type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Pts. Treat. (1998) 47:9-16.
19. THOMSSENCOPPELTP.JÄNICKEF et al: Identification of low-risk nodenegative breast cancer patients by tumorbiological factors PAI-1 and cathepsin L. Anti-Cancer Res. (1998) 18:2173-2180.
20. CARMELIET P, KIECKENS L, SCHOONJANS L etal: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.J. Clin. Invest. (1993) 92(6):2746-55.
21. CARMELIET P, SCHOONJANS L, KIECKENS L etaL: Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 368(6470):4l9-424.
22. DEWERCHINM.NUFFELENAV, WALLAYS G etaL: Generation and characterization of urokinase receptordeficient mice./ Clin. Invest. (1996) 97(3):870-878.
23. STÜRZEBECHER J;MARKWARDTF: Synthetische Inhibitoren der Serinproteasen. 17. Mitteilung. Einflu von Benzamidinderivaten auf die Aktivität der Urokinase und den Ablauf der Fibrinolyse. Pharmazie (1978) 33:599-602.
24. SPERL S, JACOB U, ARROYO DE PRADA N etaL: (4-aminomethyl)phenylguanidine derivatives as non-peptidic highly selective inhibitors of human urokinase. X-ray crystal structure of an uPA/ inhibitor complex at 1.8 A resolution. Proc. NatlAcad. Sei. USA (2000) 97:5113-5118. • Unique binding mode of a uPA inhibitor.
25. NIENABERV.WANGJ.DAVIDSOND etaL: Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite./ BioL Chem. (2000) 275:7239-7248.
26. GERATZJD, SHAVER SR.TIDWELL RR: Inhibitory effect of amidinosubstituted heterocyclic compounds on the amidase activity of plasmin and of high and low molecular weight urokinase and on urokinase-induced plasminogen activation. Thromb. Res. (1981) 24:73-83.
27. TIDWELLRR, GERATZJD, DUBOVI EJ: Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin.y. Med. Chemistry (19S3) 26:294-298.
28. BILLSTRÖM A, HARTLEY-ASP B, LECANDER I, BATRA S, ASTEDT B: The urokinase inhibitor paminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int.]. Cancer (1995) 61:542-547.
29. JANKUNJ.KECKRW.SKRZYPCZAKJANKUN E, SWIERCZ R: Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. (1997) 57:559-563.
30. VASSALLIJD, BELIN D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Letters (1987) 14:187-191.
31. TOWLEMJ,LEEA,MADUAKOREC, SCHWARTZ CE BRIDGES AJ, LITTLEFIELD BA: Inhibition of urokinase by 4-substituted benzo[£]thiophene-2carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. (1993) 53:2553-2559.
32. ALONSODF.FARIASEF.LADEDAV, DAVEL L, PURICELLIL, JOFFE EBD: Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res. Treat. (1996) 40:209-223.
33. ALONSO DF, TEJERA AM, PARIAS EF, JOFFE EBD, GOMEZ DE: Inhibition of mammary tumor cell adhesion, migration,
34. and invasion by the selective synthetic urokinase inhibitor B428. Anti-Cancer Res. (1998) 8:4499-4504.
35. • Inhibition of mammary carcinoma growth by a urokinase inhibitor.
36. RABBANI SA, HARAKIDAS P, DAVIDSON DJ, HENKIN J, MAZAR AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int.J. Cancer (1995) 63:840-845.
37. XINGRH, MAZAR A, HENKIN J, RABBANI SA: Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B428. Cancer Res. (1997) 57:3585-3593.
38. SWIERCZ R, SKRZYPCZAK-JANKUN E, MERRELL MM, SELMAN SH, JANKUN J: Angiostatic aaiviry of synthetic inhibitors of urokinase type plasminogen activator. OncoL Ref. (1999) 6:523-526.
39. TAMURASY.WEINHOUSEMI, ROBERTS CA etaL: Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Bioorg. Med. Chem, Lett. (2000) 10:983-987.
40. STÜRZEBECHER J.PRASAD, HAUPTMANN J, VIEWEG H, WILKSTRÖM P: Synthesis and structureactivity relationships of potent thrombin inhibitors - piperazides of 3amidinophenylalanine.J. Med. Chem. (1997) 40:3091-3099.
41. STÜRZEBECHER J, VIEWEG H, STEINMETZER T et ai: 3amidinophenylalanine-based inhibitors of urokinase. Koorg. Mid. Chem. Lett. (1999) 9:3147-3152.
42. ZESLAWSKAE,SCHWEINITZA, KARCHER A etaL: Crystals of the urokinase type plasminogen activator variant c-uPA in complex with small molecule inhibitors open the way towards structure based drug design.J. MoL BioL (2000) 301:465-475.
43. •• uPA crystal structure.
44. NIENABER VL, DAVIDSON D, EDALJI R
45. • Potent inhibitors with new binding mode.
46. NIENABER VL, RICHARDSON PL,
47. KLIGHOFERV, BOUSKAJJ, GIRANDA VL, GREER J: Discovering novel ligands for macromolecules using x-ray crystallographic screening. Nature Biottch. (2000)18:1105-1108.
48. APPELLAE, BLAST F: The growth factor module of urokinase is the binding sequence for its receptor. Ann. NYAcaJ. Sei. (1987)511:192-195.
49. APPELLA E, ROBINSON EA, ULLRICH SJ tt aL: The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.J. BioL Chtm. (1987) 262:4437-4440.
50. MAGDOLENV.RETTENBERGERP, KOPPITZ M étal: Systematic mutationalanalysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur.J. Biochtm. (1996)237:743-751.
51. BURGLE M, KOPPITZ M, RIEMER C et ' aL: Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. BioL Chem. (1997) 378:231-237.
52. GOODSONRJ, DOYLE MV, KAUFMAN SE, ROSENBERG S: Highaffinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Nad AcaJ. Sei. (1994) 91:7129-7133.
53. LUTHER T, MAGDOLENV, ALBRECHT S étal: Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am.]. PathoL (1997) 150(4):1231-1244.
54. LIH, LUH, GRISCELLI F et al.: Adenovirus-mediated delivery of a uPA/uPA-R antagonist suppresses angiogenesisdependent tumor growth and dissemination in mice. Gen: Ther. (1998) 5:1105-1113.
55. LIH, GRISCELUF, LINDENMEYERF et al: Systemic delivery of anriangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum. Gene Tber. (1999) 10:3045-3053.
56. MOHANPM,CHINTALASK, MOHANAM S étal: Increased invasion of neuroglioma cells transfected with urokinase plasminogen activator receptor cDNA. Cancer Res. (1999) 59:3369-3373.
57. MAD, GERARD RD, LI XY.ALIZADEH H, NIEDERKORN JY: Inhibition of metastasis of intraocular melanomas by adenovirus- mediated gene transfer of
58. plasminogen activator inhibitor Type 1 (PAI- 1) in an athymic mouse model. Blood (1997) 90:2738-2746.
59. PRAUSM,WAUTERICKXK,COLLEN D, GERARD RD: Reduaion of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gate Ther. (1999) 6:227-236.
60. BRAND K, BAKERAH, PEREZ-CANTO A et al.: Treatment of colorectal liver métastases by adenoviral transfer of tissue inhibitor of metalIoproteinases-2 into the liver tissue. Cancer Res. (2000) 60:57235730.
61. KOBAYASHIH, SUGINO D, SHE MY et al: A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. EUT. J, Biochem. (1998)253:817-826.
62. • Bifunctional inhibitor of serine pro teases and uPA/uPA-R interaction.
63. MUEHLENWEGB.ASSFALG- MACHLEIDT I, PARRADO SG et ab. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ ligand interaction. Cystatin with a urokinase receptor binding site.J. BioL Chem. (2000) 275:33562-33566.
64. • First report of a bifunctional inhibitor interfering with different proteolytic systems.
65. KOBAYASHI H, SCHMITT M, GORETZKI L etaL: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzymc urokinase-rype plasminogen activator (Pro-uPA)./ BioL Chem. (1991) 266:5147-5152.
66. ROSENBERGS: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Of in. Ther. Patents (2000) 10:1843-1852.
67. •• Review on uPA-related patents.
68. MISHIMAK,MAZARAP, GOWN A et al: A peptide derived from the nonreceptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angigogenesis in vivo in combination with cispktin. PNAS (2000) 97:8484-8489.
69. SWIERCZR,KECKRW,SKRZYPCZAKJANKUN E, SELMAN SH, JANKUN J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. OncoL Rep. (2001)8:463-470.
70. BASELGA J: Clinical trials of Hcrceptin® (trastuzurnab). Eur. J. Cancer (200l) 37(Suppl. l):18-24.
71. •• Combination therapy of a specific biological therapeutic with conventional chemotherapy.